Jiangsu Nhwa Pharmaceutical (002262) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached ¥1.46 billion, up 5.70% year-over-year.

• Net profit attributable to shareholders was ¥405.55 million, a 3.67% increase year-over-year.

• Year-to-date revenue totaled ¥4.47 billion, up 7.85% from the same period last year.

• Year-to-date net profit attributable to shareholders was ¥1.11 billion, up 8.42% year-over-year.

Financial highlights

• Basic and diluted EPS for Q3 were both ¥0.40, up 2.56% year-over-year; year-to-date EPS was ¥1.09, up 7.92%.

• Operating cash flow for Q3 was ¥911.15 million, nearly flat year-over-year.

• Total assets at quarter-end were ¥9.08 billion, up 7.58% from year-end 2024.

• Shareholders’ equity increased 11.01% to ¥8.10 billion.

• Non-recurring losses for Q3 were ¥3.62 million, mainly from other non-operating items.

Key financial ratios and metrics

• Weighted average ROE for Q3 was 5.14%, down 0.50 percentage points year-over-year.

• Year-to-date weighted average ROE was 14.31%, down 0.77 percentage points.